EndoTODAY | EndoATLAS | OPD

Parasite | Eso | Sto | Cancer | ESD

Boxim | DEX | Sono | Schedule

Home | Recent | Blog | Links

EndoTODAY ³»½Ã°æ ±³½Ç


[SAFE trial - second look endoscopy after ESD]

EndoTODAY ¾Öµ¶ÀÚ²²¼­ ÇÑ ³í¹®À» ¼Ò°³ÇØ Áּ̽À´Ï´Ù. ´Ù¼Ò ½Ä»óÇÑ ÁÖÁ¦¶óµµ ÁúÁÁÀº ÀüÇâÀû ´Ù±â°ü ¿¬±¸´Â ȯ¿µ¹Þ´Â´Ù´Â comment¿Í ÇÔ²²......

µ¿°æ´ëÇÐÀÇ Satoshi Mochizuki°¡ Á¦1ÀúÀÚÀÌ°í °°Àº ´ëÇÐÀÇ Mitsuhiro Fujishiro°¡ ±³½ÅÀúÀÚÀÎ Scheduled second-look endoscopy is not recommended after endoscopic submucosal dissection for gastric neoplasms (the SAFE trial): a multicentre prospective randomised controlled non-inferiority trial (Mochizuki S. Gut 2015)À» ESD ½Ã¼úÀÚ ÀÔÀå¿¡¼­ Àо¾Ò½À´Ï´Ù.


1. ¿¬±¸ÀÇ °á·Ð

ESD ÈÄ second look endoscopy´Â post-ESD bleedingÀ» ÁÙÀÌÁö ¸øÇß½À´Ï´Ù. Second-look endoscopy °úÁ¤¿¡¼­ ÁöÇ÷¼úÀ» ÇÑ ±×·ì°ú ÇÏÁö ¾ÊÀº ±×·ì°£ÀÇ ÃâÇ÷·ü Â÷ÀÌ´Â ¾ø¾ú½À´Ï´Ù. °á±¹ ESD ÈÄ second look endoscopyÀÇ È¿°ú´Â ºÎÁ¤µÇ¾ú½À´Ï´Ù. ÀúÀÚÀÇ ¸»À» ¿Å±é´Ï´Ù.

1. The incidences of post-ESD bleeding were 5.4% and 3.8% in the SLE and non-SLE groups, respectively; therefore, non-inferiority of the non-SLE group compared with the SLE group was confirmed with an absolute risk difference of -1.6% (two-sided 95% CI -6.7% to 3.5%, one-sided pnon-inferiority<0.001).

2. In a comparison between the groups with and without prophylactic coagulation during SLE, the proportion of patients with post-ESD bleeding was similar even when prophylactic coagulation was performed.


2. ESD ½Ã¼ú °úÁ¤

1) ³í¹®¿¡¼­ ¾ð±ÞµÈ ESD ½Ã¼ú °úÁ¤Àº Ưº°ÇÑ °ÍÀº ¾ø¾ú½À´Ï´Ù. ´Ù¸¸ ¿ì¸®³ª¶óº¸´Ù ´Ù¾çÇÑ µµ±¸°¡ »ç¿ëµÇ°í ÀÖ¾ú½À´Ï´Ù. ESD ½Ã¼úÀÚ¸¦ endoscopist·Î ºÎ¸£Áö ¾Ê°í surgeonÀ¸·Î ºÎ¸£°í ÀÖ´Â Á¡ÀÌ Æ¯ÀÌÇß½À´Ï´Ù. ÀϺ»¿¡¼­´Â ¿Ü°ú Àǻ簡 Áø´Ü ³»½Ã°æ ȤÀº ESD¸¦ ÇÏ´Â °æ¿ì°¡ ¸¹´Ù°í ÇÕ´Ï´Ù.

2) ȯÀÚ ³ªÀÌ´Â Æò±Õ 69¼¼·Î ¿ì¸®³ª¶ó ȯÀÚº¸´Ù ¾à 5¼¼ Á¤µµ °í·ÉÀ̾ú½À´Ï´Ù.

3) Á¾¾ç Å©±â´Â 15 mm, ESD specimen Å©±â´Â 40 mm¿´½À´Ï´Ù. º¸Åë Å©±â¶ó´Â ¸»¾¸ÀÔ´Ï´Ù. °áÄÚ Å©Áö ¾Ê¾Ò´Âµ¥µµ ESD procedure timeÀº 84ºÐÀ¸·Î »ó´çÈ÷ ±æ¾ú½À´Ï´Ù. Prophylatic coagulation ½Ã°£µµ 9ºÐÀ̳ª µÇ¾ú½À´Ï´Ù. ÀÌ´Â 100°³ ÀÌ»óÀÇ ESD °æÇèÀ» °¡Áø surgeonÀÌ 30%¿¡ ºÒ°úÇ߱⠶§¹®ÀÏ °ÍÀÔ´Ï´Ù. °æÇèÀÌ ÀûÀº ½Ã¼úÀÚµéÀÌ ¸¹ÀÌ Âü¿©ÇÏ¿´½À´Ï´Ù.

4) En bloc resection rate´Â 100%¿´°í curative resection rate´Â 85%¿´½À´Ï´Ù. °æÇèÀÌ ÀûÀº ½Ã¼úÀÚµéÀÌ ÃµÃµÈ÷ ½Ã¼úÀ» ÇßÁö¸¸ ±â¼úÀû °á°ú´Â ¿ì¼öÇÑ ÆíÀ̾ú½À´Ï´Ù.

5) ESD ÈÄ ÀÔ¿ø ±â°£Àº »ó´çÈ÷ ±æ¾ú½À´Ï´Ù. ESD ÈÄ day 5³ª day 6¿¡ Åð¿ø½ÃÅ°°í ÀÖ¾ú½À´Ï´Ù. ESD Àü³¯ ÀÔ¿øÇÑ´Ù°í °¡Á¤Çϸé 6¹Ú 7ÀÏ Á¤µµÀÎ ¼ÀÀÔ´Ï´Ù. Àú´Â 4¹Ú 5ÀÏ·Î ½Ã¼úÇÏ°í ÀÖ½À´Ï´Ù. ¿ì¸®³ª¶óÀÇ ¸¹Àº º´¿ø¿¡¼­´Â 3¹Ú 4ÀÏ È¤Àº ±×º¸´Ù ªÀº clinical pathway¸¦ »ç¿ëÇÏ°í ÀÖ½À´Ï´Ù. ÀϺ»Àº ¿ì¸®³ª¶óº¸´Ù ȯÀÚ¸¦ ÈξÀ õõÈ÷ Åð¿ø½ÃÅ°°í ÀÖ½À´Ï´Ù.


3. ESD ÇÕº´Áõ

1) ÃâÇ÷ÀÇ Á¤ÀÇ´Â ÀϹÝÀûÀÎ °ÍÀ̾ú½À´Ï´Ù (Clinical symptoms were defined as haematemesis, melaena or a decrease in haemoglobin of >2 g/dL). À̹ø ¿¬±¸¿¡¼­ Second look endoscopy À¯¹«°ú »ó°ü¾øÀÌ post-ESD bleedingÀº 5% Á¤µµ¿´½À´Ï´Ù. ÀÌ ¼öÁØÀº ÇÑÀÏÀÇ major center¿¡¼­ º¸ÀÌ´Â Æò±Õ Á¤µµÀÇ ÃâÇ÷·üÀÔ´Ï´Ù.

2) Èï¹Ì·Î¿î °ÍÀº post-ESD day 1 ÀÌÈÄÀÇ ÃâÇ÷, ƯÈ÷ day 5 ÀÌÈÄÀÇ ÃâÇ÷ÀÌ Á¾Á¾ ¹ß°ßµÇ¾ú´Ù´Â Á¡ÀÔ´Ï´Ù. Åë°èÀû À¯ÀǼºÀº ¾ø¾úÀ¸³ª second look endoscopy ±×·ì¿¡¼­ day 5 ÀÌÈÄÀÇ ÃâÇ÷ÀÌ ¸¹¾Ò´Ù´Â Á¡Àº ƯÀÌÇÑ Á¡ÀÔ´Ï´Ù. ¾Æ¸¶ Àǹ̰¡ ÀÖÀ» µí ÇÕ´Ï´Ù. Second look endoscopy¸¦ ÅëÇÏ¿© Áß°£¿¡ »ì¦ prophylatic treatment¸¦ Çϸé ÃâÇ÷Àº ¸·Áö ¸øÇÏ°í ´ÜÁö ´ÊÃß´Â È¿°ú°¡ ÀÖ´ÂÁö ¸ð¸£°Ú½À´Ï´Ù. °¡Àå ´Ê°Ô ÃâÇ÷ÇÑ »ç¶÷Àº ESD 14ÀÏ ÈÄ¿´½À´Ï´Ù.

3) Second look endoscopy¸¦ ÇÏ°í prophylatic hemostasis¸¦ ÇÑ »ç¶÷¿¡¼­µµ ÃâÇ÷À» ÇÑ °æ¿ì°¡ ÀÖ¾ú½À´Ï´Ù. Âü Çã¸ÁÇÑ ÀÏÀÔ´Ï´Ù. ¿Â°® ³ë·ÂÀ» Çߴµ¥ º° È¿°ú¸¦ ¸ø º» °ÍÀ̴ϱî¿ä.

4) ´Ù¸¥ ÇÕº´ÁõÀ¸·Î ¹ß¿­°ú º¹ÅëÀÌ ¾ð±ÞµÇ¾ú½À´Ï´Ù. ±×·¸½À´Ï´Ù. ¿ì¸®°¡ Á¾Á¾ ¹«½ÃÇÏÁö¸¸ º¹Åëµµ ÇÕº´ÁõÀÔ´Ï´Ù. Delayed perfoationÀÌ 1¿¹ ÀÖ¾ú½À´Ï´Ù. Âü ¹«¼­¿î ÇÕº´ÁõÀÔ´Ï´Ù.


4. ÃÑÆò

1) ESD ÇÕº´ÁõÀ» ÀüüÀûÀ¸·Î Àß »ìÆ캻 ÁÁÀº ³í¹®ÀÔ´Ï´Ù. ÀϺ»°ú ¿ì¸®³ª¶óÀÇ ESD ½Ã¼ú°úÁ¤°ú ÇÕº´Áõ ¹ß»ý·üÀº °ÅÀÇ ºñ½ÁÇÑ °Í °°½À´Ï´Ù.

2) ÀϺ»Àº ¿ì¸®³ª¶óº¸´Ù ȯÀÚ¸¦ õõÈ÷ Åð¿ø½ÃÅ°°í ÀÖ¾ú½À´Ï´Ù. ¿ì¸®´Â ³Ê¹« ¼­µÑ·¯¼­ ¹®Á¦°í, ÀϺ»Àº ³Ê¹« ´À±ßÇؼ­ ¹®Á¦ÀÔ´Ï´Ù.

3) °á·ÐÀº À۳⿡ ¹ßÇ¥µÈ ¿ì¸®³ª¶ó ¿¬±¸¿Í Å©°Ô ´Ù¸£Áö ¾Ê¾Ò½À´Ï´Ù. Ryu et al. Second-look endoscopy is not associated with better clinical outcomes after gastric endoscopic submucosal dissection: a prospective, randomized, clinical trial analyzed on an as-treated basis (PMID: 23531425). Ryu µîÀÇ ¿¬±¸´Â ´ÜÀϱâ°ü¿¬±¸¿´°í ÃâÇ÷·üÀÌ ´Ù¼Ò ³ô¾Ò´Ù´Â Á¡¿¡ Â÷ÀÌ°¡ ÀÖÀ» »ÓÀÔ´Ï´Ù.

4) ¸ðµç ȯÀÚ¿¡¼­ ÀÏ°ýÀûÀ¸·Î second look endoscopy¸¦ ÇÏ´Â °ÍÀº ±Ù°Å°¡ ºÎÁ·ÇØ º¸ÀÔ´Ï´Ù. Second look endoscopy´Â ¾Æ¿¹ clinical pathyway¿¡¼­ ºüÁö°Å³ª ȤÀº ¼Ò¼öÀÇ °íÀ§Çè ȯÀÚ¿¡¼­¸¸ ¼±ÅÃÀûÀ¸·Î ½ÃÇàµÇ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇØ º¸ÀÔ´Ï´Ù.


[References]

1) EndoTODAY ESD ÈÄ ÃâÇ÷

2) EndoTODAY SLE (second look endoscopy) after ESD

© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.